drugset / Trial / NCT03043001

Memantine in Bipolar Patients With Alcoholism

NCT03043001

Phase 3 Unknown 60 enrolled National Cheng-Kung University Hospital
NaSingle-groupOpen-labelTreatment

Summary

Since memantine may not only inhibit overactivity of microglial cell, but also repair the damaged neurons and neurogenesis through activation of astroglial cell and release of neurotrophic factors, the investigators propose that the neurotrophic effect of memantine may benefit neurodegenerative diseases including bipolar disorders (BP) and alcohol dependence. In the current study, the investigator will investigate whether add-on memantine at a dose of 5 mg/day has a beneficial effect on BP comorbid with alcohol dependence.

Timeline

Start
2014-01-01
Primary completion
2016-12-31
Completion
2017-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 5 mg

Indications

No indication recorded.